Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to learn if sorbitol works to enhance the therapeutic effect of neoadjuvant chemotherapy combined with Tirellizumab (PD-1 inhibitor) in patients with locally advanced gastric cancer. It will also learn about the safety of sorbitol. The main questions it aims to answer are: Does sorbitol enhance the therapeutic effect of immunotherapy and increase the major response rate in patients with locally advanced gastric cancer? Does sorbitol with neoadjuvant chemotherapy combined with Tirellizumab (PD-1 inhibitor) can improve the prognosis of patients with locally advanced gastric cancer? Researchers will compare sorbitol to a standard-of-care treatment (aPD-1 + SOX chemotherapy) to see if sorbitol works to enhance the therapeutic effect (Add-on Effect) of neoadjuvant chemotherapy combined with Tirellizumab (PD-1 inhibitor) in patients with locally advanced gastric cancer. Participants will: Take sorbitol every day for 3 months in 3 treatment cycles Visit the clinic once every 4 weeks for checkups and tests Keep a diary of their symptoms and the number of times they use a rescue inhaler Participants will follow up as planned until PD occurs, informed consent is withdrawn, or follow-up is lost (whichever occurs first). After the end of treatment and safety follow-up, all subjects will be followed up for survival (OS data collected every 3 months ±14 days).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 70 lat
- •Potwierdzony histologicznie rak żołądka lub połączenia żołądka z przełykiem, wcześniej nie leczony
- •Zaawansowana postać nowotworu (stadium T3-4N+M0)
- •Dobry ogólny stan zdrowia (ECOG 0-1)
- •Prawidłowe wyniki badań krwi i funkcji narządów wewnętrznych
- •Dla kobiet: ujemny test ciążowy i gotowość do antykoncepcji przez czas badania i 8 tygodni po
- •Brak przerzutów do odległych narządów
- •Pisemna zgoda na udział w badaniu
✗ Disqualifies
- •Przerzuty do odległych narządów lub otrzewnej
- •Aktywne lub przebyte choroby autoimmunologiczne (zapalenie jelit, łupież rumieniowaty, reumatoidalne zapalenie stawów, zapalenie pęcherzyków ocznych)
- •Obecne lub wcześniejsze zapalenia (zapalne choroby jelit, zapalenie wyrostka robaczkowego, zespół Granulomatozy)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 70 Years
- Last updated (source)
- August 18, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Trial contact
Yao Lin, Dr.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/19/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.